Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Cardiology

• Publication date

  2017-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijcard.2016.10.084PMID 27810295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.

  2016cited by this paper
• Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor.

  2016cited by this paper
• Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

  2016cited by this paper
• From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.

  2016cited by this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome

  2016cited by this paper
• Platelet-Mediated Thrombosis: From Bench to Bedside.

  2016cited by this paper
• Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

  2016cited by this paper
• PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR

  2016cited by this paper
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

  2015cited by this paper
• Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

  2015cited by this paper
• Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes

  2014cited by this paper
• Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality.

  2014cited by this paper
• Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat

  2014cited by this paper
• Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes

  2013cited by this paper
• Third universal definition of myocardial infarction

  2013cited by this paper
• Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.

  2013cited by this paper
• Third universal definition of myocardial infarction.

  2012cited by this paper
• Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study

  2012cited by this paper
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

  2011cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up

  2009cited by this paper
• Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes.

  2009cited by this paper
• Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry

  2008cited by this paper
• Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype

  2007cited by this paper
• Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions

  2007cited by this paper
• Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

  2006cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia

  2004cited by this paper
• Antiplatelet therapy for ischemic heart disease.

  2004cited by this paper
• Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

  2004cited by this paper
• Differential effects of native and oxidatively modified low-density lipoproteins on platelet function.

  1997cited by this paper
• Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia.

  1993cited by this paper

• The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

  2026cites this paper
• Adverse Events Associated with Inclisiran: A Real-world pharmacovigilance study of FDA adverse event reporting system (FAERS).

  2025cites this paper
• Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

  2025cites this paper
• The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis

  2025influential citation
• CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis

  2025cites this paper
• Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled Studies

  2025cites this paper
• The Effects of Inclisiran on the Subclinical Prothrombotic and Platelet Activation Markers in Patients at High Cardiovascular Risk

  2025cites this paper
• Causal Relationship between PCSK9 Inhibitor and Atrial Fibrillation/ A Drug Target Mendelian Randomization Study

  2025cites this paper
• Research Progress of PCSK9 in Clinical Practice

  2025cites this paper
• Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study

  2025cites this paper
• Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome

  2024cites this paper
• Platelets as an inter‐player between hyperlipidaemia and atherosclerosis

  2024cites this paper
• Lipid-Lowering Therapy after Acute Coronary Syndrome

  2024cites this paper
• The Lipid–Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet Reactivity

  2024cites this paper
• Efficacy and Safety of PCSK9 Inhibitors for Stroke Prevention: Systematic Review and Meta-Analysis.

  2024cites this paper
• Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?

  2024cites this paper
• PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke

  2024cites this paper
• Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome

  2024influential citation
• PCSK9 Inhibitors: Is the Time Ripe for the “Fast Track” Use Independently on the LDL-C Baseline Values in Acute Coronary Syndrome?

  2024cites this paper
• Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications.

  2024cites this paper
• Association of Circulating PCSK9 With Ischemia-Reperfusion Injury in Acute ST-Elevation Myocardial Infarction

  2024cites this paper
• Is PCSK9 the Key Player in the Ischemia-Reperfusion Match?

  2024cites this paper
• Percorso diagnostico e terapeutico della dislipidemia nel paziente ad alto rischio cardiovascolare

  2024cites this paper
• Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9

  2024influential citation
• The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol

  2024cites this paper
• Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review)

  2024cites this paper
• Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review

  2024cites this paper
• PCSK9 as an Atherothrombotic Risk Factor

  2023cites this paper
• Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)

  2023influential citation
• Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.

  2023cites this paper
• High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study

  2023cites this paper
• Early Addition of Evolocumab to Statin Treatment in Patients with Acute Coronary Syndrome and Multivessel Disease Undergoing Percutaneous Coronary Intervention

  2023cites this paper
• The Anti-Thrombotic Effects of PCSK9 Inhibitors

  2023cites this paper
• Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial

  2023cites this paper
• The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function

  2023cites this paper
• Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition.

  2023cites this paper
• Targeting PCSK9 to tackle cardiovascular disease.

  2023cites this paper
• Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review

  2023cites this paper
• In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?

  2023cites this paper
• PCSK9 inhibition in atherosclerotic cardiovascular disease.

  2023cites this paper
• Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes

  2023influential citation
• Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

  2023cites this paper
• Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome

  2022cites this paper
• PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction

  2022cites this paper
• Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis

  2022cites this paper
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis

  2022influential citation
• A Comprehensive Review of PCSK9 Inhibitors

  2022influential citation
• Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes

  2022cites this paper
• Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall

  2022influential citation
• Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies

  2022cites this paper
• Oxidised Low-Density Lipoprotein-Induced Platelet Hyperactivity—Receptors and Signalling Mechanisms

  2022cites this paper
• Sex difference in circulating PCSK9 and its clinical implications

  2022influential citation
• Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9.

  2022cites this paper
• Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell

  2022cites this paper
• Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents

  2022cites this paper
• PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis.

  2022cites this paper
• In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

  2022cites this paper
• Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?

  2022cites this paper
• Drug–Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)

  2022cites this paper
• Elevated plasma proprotein convertase subtilisin/kexin type-9 is associated with poor prognosis of acute myocardial infarction in hypertension patients

  2022cites this paper
• Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis

  2021cites this paper
• Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis

  2021cites this paper
• The impact of the PCSK-9/VLDL-Receptor axis on inflammatory cell polarization.

  2021cites this paper
• Proprotein Convertase Subtilisin Kexin Type 9

  2021cites this paper
• PCSK9 inhibition for acute arterial events: more than LDL lowering.

  2021cites this paper
• Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention.

  2021cites this paper
• PCSK9 inhibition could be effective for acute myocardial infarction.

  2021cites this paper
• PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology

  2021cites this paper
• Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients

  2021cites this paper
• Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy

  2021cites this paper
• PCSK9 Biology and Its Role in Atherothrombosis

  2021cites this paper
• Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia

  2021cites this paper
• Prognostic Value of PCSK9 Levels in Non-ST elevation myocardial infarction Patients Undergoing Percutaneous Coronary Intervention (PCI).

  2021cites this paper
• PCSK9: a view beyond the canonical cholesterol lowering impact.

  2021cites this paper
• Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

  2021cites this paper
• The local effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the inflammatory atheroma: beyond LDL cholesterol lowering

  2021cites this paper
• Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art

  2021cites this paper
• PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

  2021cites this paper
• Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up.

  2020cites this paper
• Lipid-lowering therapy: guidelines to precision medicine.

  2020cites this paper
• Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

  2020cites this paper
• PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders

  2020cites this paper
• PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.

  2020cites this paper
• Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits

  2020cites this paper
• Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall

  2020cites this paper
• Novel Approaches to Fine-Tune Therapeutic Targeting of Platelets in Atherosclerosis: A Critical Appraisal

  2020cites this paper
• Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients

  2020cites this paper
• Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

  2020cites this paper
• PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation

  2020cites this paper
• Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition

  2020influential citation
• Influence of Cardiometabolic Risk Factors on Platelet Function

  2020cites this paper
• Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation

  2019cites this paper
• Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort.

  2019cites this paper
• Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics.

  2019cites this paper
• PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention

  2019cites this paper
• Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?: JACC Review Topic of the Week.

  2019cites this paper
• Nano-scaled MTCA-KKV: for targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo

  2019cites this paper
• Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study

  2019cites this paper
• Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction

  2019cites this paper
• Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing

  2019cites this paper